FI925804A - Immunologiskt reaktiv foerening - Google Patents

Immunologiskt reaktiv foerening Download PDF

Info

Publication number
FI925804A
FI925804A FI925804A FI925804A FI925804A FI 925804 A FI925804 A FI 925804A FI 925804 A FI925804 A FI 925804A FI 925804 A FI925804 A FI 925804A FI 925804 A FI925804 A FI 925804A
Authority
FI
Finland
Prior art keywords
foerening
immunological reactive
immunological
reactive
reactive foerening
Prior art date
Application number
FI925804A
Other languages
English (en)
Other versions
FI925804A0 (fi
Inventor
Ebo Sybren Bos
Petrus Johannes Boon
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of FI925804A publication Critical patent/FI925804A/fi
Publication of FI925804A0 publication Critical patent/FI925804A0/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI925804A 1990-07-03 1992-12-21 Immunologiskt reaktiv foerening FI925804A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90201781 1990-07-03
PCT/EP1991/001223 WO1992000763A1 (en) 1990-07-03 1991-06-28 Immunoreactive compound

Publications (2)

Publication Number Publication Date
FI925804A true FI925804A (fi) 1992-12-21
FI925804A0 FI925804A0 (fi) 1992-12-21

Family

ID=8205056

Family Applications (1)

Application Number Title Priority Date Filing Date
FI925804A FI925804A0 (fi) 1990-07-03 1992-12-21 Immunologiskt reaktiv foerening

Country Status (7)

Country Link
EP (1) EP0537222A1 (fi)
JP (1) JPH05507924A (fi)
KR (1) KR930701201A (fi)
CA (1) CA2086531A1 (fi)
FI (1) FI925804A0 (fi)
HU (1) HUT63343A (fi)
WO (1) WO1992000763A1 (fi)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824632D0 (en) * 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU556548B2 (en) * 1980-03-03 1986-11-06 Milton David Goldenberg Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers
CA1168150A (en) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
NZ210867A (en) * 1984-01-31 1989-01-06 Litton Bionetics Inc Tumour-specific monoclonal antibodies, production thereof and use
EP0293524A1 (en) * 1987-06-02 1988-12-07 Vasocor Atherosclerotic plaque immunoassay
EP0295719A3 (en) * 1987-06-19 1989-12-20 The Agouron Institute The sm-d antigen, the cloning of the sm-d antigen and the detection of systemic lupus erythematosus by using the sm-d antigen
ATE82136T1 (de) * 1987-08-10 1992-11-15 Miles Inc Gereinigtes igm.
US4937183A (en) * 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
EP0398872A1 (en) * 1988-02-12 1990-11-28 HighTech Receptor AB Immunoglobulin binding substance, subfragments, a process for preparing thereof, reagent kit and immunoglobulin binding organisms
US4983529A (en) * 1988-06-10 1991-01-08 Abbott Laboratories Immunoassay for HIV-I antigens using F(AB')2 fragments as probe
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
WO1990011091A1 (en) * 1989-03-27 1990-10-04 Centocor, Inc. FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES

Also Published As

Publication number Publication date
HU9204170D0 (en) 1993-04-28
WO1992000763A1 (en) 1992-01-23
JPH05507924A (ja) 1993-11-11
KR930701201A (ko) 1993-06-11
EP0537222A1 (en) 1993-04-21
CA2086531A1 (en) 1992-01-04
FI925804A0 (fi) 1992-12-21
HUT63343A (en) 1993-08-30

Similar Documents

Publication Publication Date Title
ATA150090A (de) Hoergeraet
DE4141638B4 (de) Fluidzerstäubungsvorrichtung
FI930894A0 (fi) Form foer flotationsprodukter
ATA99891A (de) Vollauszug
ATA210290A (de) Lotpille
DE69123556D1 (de) Reaktivfarbstoffe
BR9102325A (pt) Ebulidor
BR9101214A (pt) Ministrador
ATA80690A (de) Alpinschi
FI925804A0 (fi) Immunologiskt reaktiv foerening
ATA200090A (de) Pianino
ATA209290A (de) Diaraehmchen
BR9103647A (pt) Tioesteres
ATA237490A (de) Rinnenstein
BR9003611A (pt) Hidrobaliador
FI932980A (fi) Fasthaollningsdon
BR9002505A (pt) Venturbo
BR9000230A (pt) M equilibrista
MX9102026A (es) Colorantes reactivos
ATA70290A (de) Anzeigetafel
BR7001392U (pt) Lixa
BR9004055A (pt) Arquibancada-retratil
BR7000286U (pt) Barraca-bagageiro
BR7000375U (pt) Mosquiteiro baby-ju
BR9006686A (pt) Sincrometro